Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, An Investigational Oral Brain-Penetrant Selective Inhibitor Of Mutant IDH1

20 Aug 2026 · 12:05 UTC

Observed price moves

NUVB-2.27%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.